Clinical trials: Lung Carcinoma
ccRCC
Prognostic Significance of the Lung Immune Prognostic Index (LIPI) in Postoperative Clear Cell Renal Cell Carcinoma: a Multicenter Retrospective Cohort Study
This retrospective study included 704 patients with ccRCC who underwent radical or partial nephrectomy. Patients were stratified into the LIPI good group and the intermediate/poor (int./poor) group based on dNLR (≥ 3) and LDH (≥…
- Trial name
- NCT06775574
- Where
- China
- Volunteers
- 704 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Neuroendocrine Tumors, Progression
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Everolimus is approved in many countries to treat patients with advanced/metastatic well-differentiated neuroendocrine tumors (NET), providing median progression-free survival times of approximately 12 months across different…
- Conditions
- Neuroendocrine Tumors, Progression, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2
- Trial name
- EVENET (NCT06472388)
- Testing
- Everolimus 5 MG
- Where
- 2 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- AC Camargo Cancer Center
Lung Cancer
The Impact of Lung Cancer-derived Fibroblasts on Mast Cells Activation
In addition to their role in allergic inflammation, mast cells are often found at the site of tumors. They have been attributed both to pro- and anti-tumorigenic roles depending on the tumor type.
- Trial name
- NCT02161523
- Volunteers
- 20 people
- Sponsor
- Meir Medical Center
Carcinoma, Non-Small-Cell Lung
Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Clinical Early Stages of Non-small Cell Lung Cancer
Randomized Phase III trial of surgery alone or surgery plus preoperative Gemcitabine-Cisplatin in clinical early stages of non-small cell lung cancer
- Trial name
- NCT00540280
- Testing
- Surgery alone or surgery plus preoperative Gemcitabine-Cisplatin
- Volunteers
- 10 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Lung Cancer
Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in Thailand
The purpose of this study is to determine progression-free survival of lung cancer patients who received gefitinib in clinical practice in Thailand.
- Trial name
- NCT01130961
- Where
- Thailand
- Volunteers
- 104 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Evaluate EGFR Mutation Status and Impact Factors in North China
Approximately 3000 advanced NSCLC patients, who fulfil the inclusion/exclusion criteria, will be recruited by 30 sites in North China.
- Trial name
- NCT02620657
- Testing
- Non interventional study
- Volunteers
- 2,809 people
- Sponsor
- ying cheng
Non-Small-Cell Lung Cancer
The Evaluation of Lung Cancer Patient Treated With Epidermal Growth Factor Receptor Tyrosine Kinase
To evaluate Non-Small Cell Lung Cancer (NSCLC) patients clinical profile and the outcome after treatment with Gefitinib in Pulmonary Oncology Outpatient Clinic Dr. Soetomo General Hospital, Surabaya, Indonesia.
- Trial name
- EVALUATE (NCT02755337)
- Where
- Indonesia
- Volunteers
- 70 people
- Sponsor
- Dr. Soetomo General Hospital
Lung Cancer
Demographics of Lung Cancer in Females
Lung cancer has been the most common and fatal type of cancer; indeed worldwide incidence of lung cancer is alarming. It is considered a leading cause of cancer- related deaths among males and females due to environmental…
- Trial name
- NCT07122245
- Testing
- Demographics and risk factors of lung cancer
- Where
- Egypt
- Volunteers
- 300 people
- Sponsor
- Mansoura University Hospital
Advanced Non-Small Cell Lung Cancer
The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer
The purpose of this study is to compare the overall survival of patients with advanced non small cell lung cancer treated with docetaxel as single therapy versus docetaxel in combination with either gemcitabine or vinorelbine or…
- Trial name
- DISTAL-2 (NCT00345059)
- Testing
- docetaxel, vinorelbine, gemcitabine
- Where
- 24 sites in Italy
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute, Naples
Lung Cancer, Malignant Mesothelioma
Alanosine in Treating Patients With Cancer
RATIONALE: Drugs used in chemotherapy such as alanosine use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer, Sarcoma
- Trial name
- NCT00062283
- Testing
- L-alanosine
- Where
- 12 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neuroendocrine Carcinoma of Lung, Neuroendocrine Carcinoma of Thymus
CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors
The study involves the enrollment of 34 patients diagnosed with advanced thymic, pulmonary and duodeno-pancreatic well-differentiated high grade neuroendocrine tumors (Ki-67 > 20%).
- Trial name
- LINEAR (NCT07429851)
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- European Institute of Oncology
Pain, Postoperative
Exploring the Effects of Transcutaneous Electrical Acupoint Stimulation Therapy on Patients After Video-Assisted Thoracoscopic Surgery
Thoracic surgery is known to be one of the most painful types of surgery. If acute postoperative pain is not properly managed, there is a high risk that it may develop into clinically significant chronic pain within six months…
- Trial name
- NCT07287657
- Testing
- Standard Analgesia, Transcutaneous Electrical Nerve Stimulation (TENS), Transcutaneous Electrical Acupoint Stimulation (TEAS)
- Where
- Taiwan
- Volunteers
- 96 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Lung Adenocarcinoma, Surgical Procedure, Unspecified
Intraoperative Frozen Section Pathology to Diagnose the IASLC Grades for Lung Adenocarcinoma (ECTOP-1014)
This study is one of Eastern Cooperative Thoracic Oncology Projects (ECTOP-1014). The goal of this clinical trial is to confirm the concordance rate between intra-operative frozen section pathological diagnosis and post-operative…
- Conditions
- Lung Adenocarcinoma, Surgical Procedure, Unspecified, Pathology
- Trial name
- NCT05794698
- Testing
- Surgical resection
- Where
- China
- Volunteers
- 827 people
- Sponsor
- Fudan University
NSCLC Stage IV
T790M Mutation Testing in Blood by Different Methodologies
Three laboratories will participate in the study. Each laboratory will analyze the same samples by different methodologies according to the flow indicated in figure 1.
- Trial name
- NCT03363139
- Testing
- Tirosin Kinase Inhibitors
- Where
- 30 sites in Spain
- Volunteers
- 72 people
- Sponsor
- Spanish Lung Cancer Group
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back.
- Conditions
- Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma
- Trial name
- NCT03845296
- Testing
- Rucaparib
- Where
- 950 sites in United States
- Volunteers
- 64 people
- Sponsor
- SWOG Cancer Research Network
Non Small Cell Lung Cancer
Incidence and Characterization of Drivers Oncogenes in the Population With Lung Cancer Afferents to the Cancer Institute in Aviano (IN.ON.D.)
According to an analysis by Memorial Sloan Kettering Cancer Center patients who receive a target therapy having an oncogenic driver mutation live longer than those who do not receive it.
- Trial name
- INOND (NCT06180005)
- Where
- Italy
- Volunteers
- 700 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Nonsmall Cell Lung Cancer
CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor Histology
Lung cancer remains the leading cause of cancer related mortality worldwide, with more than 1.5 million related deaths annually.
- Trial name
- NCT03940846
- Testing
- Virtual biopsy
- Where
- Netherlands
- Volunteers
- 650 people
- Sponsor
- Maastricht University
Carcinoma, Non-Small-Cell Lung
Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer
Objective: L-[3-18F]-α-methyltyrosine (FMT) is an amino-acid tracer for PET. We evaluated the diagnostic usefulness of 18F-FMT PET in non-small cell lung cancer (NSCLC) patients.
- Trial name
- NCT00464282
- Sponsor
- Gunma University
Breast Neoplasms, Colonic Neoplasms
A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab
This is a phase II clinical and pharmacokinetic study of suppression of human antimouse (HAMA) and antitoxin antibodies (HATA) to immunotoxin LMB-1 by Rituximab (anti-CD20).
- Conditions
- Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Pancreatic Neoplasms
- Trial name
- NCT00001805
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)